Complications and Safety Profile of Posterior SubTenon Injection of Triamcinolone Acetonide

Abstract

Purpose: Posterior Sub-Tenon injection (PSTI) is a common route of drug delivery for triamcinolone acetonide (TA) for intraocular inflammation. The aim of this study was to evaluate indications, complications and safety of PSTI of TA for intraocular inflammation. Method: This is a retrospective study. The duration of study was from October 2007 to December 2016. The patients with minimum 1 year after PSTI of TA follow-up were included in the study. All complications of injection procedure and drug itself were included. Patients with pre-existing lenticular opacity, glaucoma, blepharoptosis, traumatic macular edema, subconjunctival hemorrhage, traumatic uveitis, postoperative uveitis, and retinal vascular occlusive disorder were excluded from the study. Results: A total of 112 eyes of 110 patients who were treated with PSTI of TA were included in the study group. The mean age was 50±8.4 years. Out of 110 patients, 80 (72.72%) were females and 30 (27.27%) males. The recurrent anterior uveitis was the most common indication (44.64%). Out of 112 eyes, 100 eyes (89.28%) were injected once, 10 eyes (8.92%) twice, and 2 eyes (1.78%) thrice. Following PSTI of TA, 14 eyes (12.5%) developed ocular hypertension 6 eyes (5.35%) ptosis, and 3 eyes (2.67%) cataract. Conclusion: PSTI of TA has higher risk of steroid-induced glaucoma; hence these patients should be monitored for intraocular pressure.